We suggest that imatinib and other selective PDGF receptor inhibitors (e.g., dasatinib) might prove beneficial when combined with VEGF receptor inhibitors and/or with chemotherapy in more flexible combinations than strictly simultaneous dosing, involving evolutions of the chemo-switch regimen [36]; thus we might imagine first normalizing the tumor vasculature with VEGF pathway inhibitors [65], then applying high-dose (standard-of-care) chemotherapy, and finally introducing PDGF receptor inhibitors, alone or in combination with VEGF inhibitors or low-dose metronomic chemotherapy. This evidence concerns the gene VEGFA and neoplasm.